Brochure
11 Nov 2023
Alteogen signs global licence deal with Sandoz
Sandoz will have global rights to use Alteogen’s ALT-B4 to develop and commercialise a subcutaneous version of a biosimilar product.
Content provided by our supplier
Alteogen
-
Country/Region:Korea, Republic Of
-
On CPHI since:2023